top of page
Search

PPM's Candid Conversations | Exclusive Interview with Bolu Oladini

Updated: Feb 21





PPM had the opportunity of speaking with Bolu Oladini, a pharmacist by training who’s now the Director and Generative AI Medical Content Lead at Pfizer. His career has taken him through patient care, medical communications, and medical strategy, giving him a broad perspective on the healthcare industry. Here are the key takeaways from the interview:


Current Work with AI in Medical Communications:

Bolu's team utilizes generative AI to modernize and enhance medical content, focusing on scientific publications, plain language summaries, and medical-to-medical communications. AI is employed to address information overload among clinicians and improve the accessibility of critical information.

 

Challenges and Opportunities in AI Implementation:

Challenges: Resistance to AI adoption often stems from fear and misconceptions, such as concerns over job displacement or reduced human oversight. Organizational silos and a lack of integrated collaboration between AI experts and subject matter experts hinder the scaling of AI solutions.

 

Opportunities: AI presents opportunities in drug discovery, clinical trial design, medical content generation, and operational efficiencies. The industry's success will hinge on proactive adoption, fostering collaboration across functions, and rethinking organizational structures to integrate AI effectively.

 

Advice for Stakeholders and Students:

Bolu emphasized the importance of embracing AI with curiosity and an open mind, viewing it as a tool for efficiency rather than a threat. He encouraged stakeholders to focus on skills that AI cannot replicate, such as emotional intelligence and relationship-building.


For students, he highlighted the value of developing critical thinking and adaptability to remain competitive in an evolving healthcare landscape.

 

Future Needs and Implementation Priorities:

The pharmaceutical industry must prioritize organizational restructuring to better integrate AI into core functions, breaking down silos and fostering collaboration between AI and subject matter experts.


Immediate needs include addressing perceptions of AI, building scalable use cases, and ensuring effective change management. Long-term success will require aligning AI strategies with broader business objectives and operationalizing AI at scale.


What are your thoughts on these opportunities and challenges?


Disclaimer:

The opinions, views, and statements expressed by Bolu Oladini, Director and Generative AI Medical Content Lead at Pfizer, during this interview are solely his own and do not necessarily reflect the opinions, positions, or policies of Pfizer or any of its affiliates. All comments are made in his personal capacity and should not be interpreted as official statements, endorsements, or representations of the company. Any reference to Bolu Oladini’s professional background is provided for contextual purposes only and does not imply Pfizer’s involvement or endorsement of the views expressed.





Comments

bottom of page